Mayer Brown announced today that it advised Fresenius Kabi, a leading provider of infusion therapy and clinical nutrition, on its definitive agreement to acquire Fenwal Holdings, Inc., a global leader specializing in separation technologies for blood and cell collection and therapy with operations throughout North America, Latin America, Europe and Asia. The acquisition is expected to close by the end of the year. Financial terms of the agreement were not disclosed.
The Mayer Brown team included: Corporate & Securities – partners David Carpenter (New York), John Boelter (Chicago) and Christof Gaudig (Düsseldorf) and associates Michael Torres, Lindsey Magaro, Jen Rhein (Chicago) and Jan Streer (Düsseldorf), and registered foreign lawyer Edward Leung (Hong Kong); IP – partner Joseph Mahoney and associate Jonathan Kim (Chicago); Antitrust & Competition – partner John Roberti (Washington, DC); and Tax Transactions & Consulting – partner Lee Morlock (Chicago).
